Personalized dosing of cancer and infection drugs in children with blood cancers
Official title: Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Run by Shandong University · NCT03844360 · Data updated 2026-11-12
This study is testing if giving children with blood cancers personalized doses of their cancer and infection medications can improve their treatment results and safety.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 1 Day to 18 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Shandong University Academic / other |
| Locations | 2 sites (Xuzhou, Jiangsu and 1 other locations) |
| Status | Recruiting |
| Started | January 31, 2016 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | March 30, 2025 |
| Trial ID | NCT03844360 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children diagnosed with hematological neoplasms who are undergoing treatment with antineoplastic or anti-infective drugs.
✕Probably not a fit
Patients with a life expectancy of less than the treatment cycle or those deemed unsuitable by the researchers may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the feasibility of customizing dosages of commonly used antineoplastic and anti-infective medications for children diagnosed with hematological neoplasms. By employing an opportunistic sampling strategy, the researchers will assess how individualized dosing can improve treatment outcomes. The study will involve various interventions, including drugs like Bortezomib and Imatinib, to determine the most effective dosages for each patient. The goal is to enhance the efficacy and safety of treatments in this vulnerable population.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer treatment regimens for children with hematological cancers.
How similar studies have gone: While the approach of dosage individualization is gaining traction, this specific study's methodology is relatively novel and has not been extensively tested in similar populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be diagnosed with hematological neoplasms * Antineoplastic drugs or anti-infective drugs used as part of regular treatment Exclusion Criteria: * expected survival time less than the treatment cycle; * patients with other factors that researcher considers unsuitable for inclusion.
Where it's running
-
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tanjin, Tianjin Municipality, China Recruiting -
Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China Completed
Study contacts
- Principal investigator: Wei Zhao, Ph.D — Shandong University
- Study coordinator: Wei Zhao, Ph.D
- Email: zhao4wei2@hotmail.com
- Phone: 86053188383308
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Virtual reality to distract from pain and anxiety during blood cancer procedures
This project tries whether wearing a virtual reality headset during procedures can reduce pain and anxiety for people aged 6 and older with blood cancers.
-
Personalized T cells engineered to target TP53 or RAS mutations in blood cancers
This trial will try using a patient's own T cells, modified to recognize specific TP53 or RAS mutations, to treat adults with certain blood cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.